Document Detail


A population-based European cohort study of persistence in newly diagnosed hypertensive patients.
MedLine Citation:
PMID:  12149663     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study assessed the percentage of patients after 1 year who persisted on initially prescribed antihypertensive therapy. Medical records of 2416 patients with newly diagnosed hypertension who were prescribed initial antihypertensive monotherapy by general practitioners in Germany, France, and the United Kingdom were evaluated. Comparisons were made among the angiotensin II receptor antagonist (AIIRA) irbesartan, all other antihypertensive classes (including AIIRAs other than irbesartan), and the AIIRA losartan. Patients initiated on the AIIRA irbesartan scored highest with a persistence rate of 60.8%, followed by patients who received all other AIIRA agents with a persistence rate of 51.3%. Angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and losartan were associated with comparable persistence rates, between 42.0% and 49.7%. Patients who received diuretics scored lowest with a persistence rate of 34.4%. Persistence has emerged as an essential factor for blood pressure control. Prescribing an antihypertensive agent that provides a favourable efficacy and tolerability profile may provide greater persistence with therapy and hence a higher level of blood pressure control.
Authors:
J Hasford; A Mimran; W R Simons
Related Documents :
9606283 - Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically tr...
15815773 - Coronary flow velocity reserve is diminished in hypertensive left ventricular hypertrophy.
21789553 - Cavernous vessels around a patent portal trunk in the liver hilum.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of human hypertension     Volume:  16     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-07-31     Completed Date:  2002-11-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  569-75     Citation Subset:  IM    
Affiliation:
Department for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany. has@ibe.med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Biphenyl Compounds / therapeutic use*
Calcium Channel Blockers / therapeutic use
Cohort Studies
Europe / epidemiology
Female
Humans
Hypertension / drug therapy*,  epidemiology*
Losartan / therapeutic use*
Male
Middle Aged
Receptors, Angiotensin / antagonists & inhibitors*,  therapeutic use*
Retreatment
Tetrazoles / therapeutic use*
Treatment Failure*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Calcium Channel Blockers; 0/Receptors, Angiotensin; 0/Tetrazoles; 114798-26-4/Losartan; 138402-11-6/irbesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relationship between blood pressure and blood lead in NHANES III. National Health and Nutritiona...
Next Document:  Factors related to non-compliance with antihypertensive drug therapy.